CRISPR Therapeutics Company

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.
CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Technology: Gene therapy
Industry: Regenerative Medicine
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2013
Employees Number: 1-10
Funding Status: IPO

Visit Website
info@crisprtx.com
@crisprtx
Register and Claim Ownership